Quote
146.41
+2.69 (+1.87%)
We have scored 82 news catalysts on GILD (GILD) over the past 12 months. Coverage across the window leans positive (average ticker sentiment +0.30). Most of the impact sits in sector healthcare and price momentum.
Market cap
—
P/E
—
EPS
—
Beta
—
52W range
—
Day range
144.19–146.75
Open
145.56
Prev close
143.72
Volume
4.9M
Avg volume
—
Dividend
—
IPO
—
No scored news tagged GILD or its network in the window yet.
Show more GILD articles →Analysts publish price targets on GILD, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
10 analyst price targets from $120 to $166
as of 2026-09-10
The market is within 1% of the median target — broadly agreeing with the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about GILD — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of GILD, taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for GILD: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The price sits within 1% of the median published target, meaning it broadly agrees with the middle of the analyst spread and has already paid for the base-case scenario of steady HIV revenue and current cash flows.
What the disagreement turns on
Whether cell therapy revenue can reverse its 8.1% year-over-year decline and whether the near-term pipeline can accelerate total revenue growth above the 6.6% the price already requires — and unit volume data wired to this tool can actually track both.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
